Abstract:Eighty basal cell carcinomas (BCCs) in 21 patients, 10 lesions of Bowen's disease in three patients, and four lesions of cutaneous T-cell lymphoma in two patients, were treated with photodynamic laser therapy (PDT), using topical application of the haem precursor delta-amino levulinic acid (ALA). The diagnoses were confirmed histologically prior to treatment. Fifty-five of the BCCs were superficial lesions, and 25 were nodular. Of the 80 BCCs, 39 (49%) were located on the trunk, 36 (45%) on the head and neck region, four (15%) on the leg and one on the arm. The two principal locations of the 10 Bowen's disease lesions were the leg (50%) and the trunk (40%). The T-cell lymphoma lesions were located on the shoulder and on the arm. A water-in-oil based cream containing 20% ALA was applied to the lesions, with a margin of about 10-20 mm beyond the visible tumour border, 4-6 h before the laser procedure. During this period of time the highly fluorescent and photodynamically active substance protoporphyrin IX (Pp IX) is synthesized via the haem cycle. Laser-induced fluorescence (LIF) was used for real-time monitoring of the Pp IX distribution in the tumour and in the normal surrounding skin, before and after treatment in all patients. Before laser treatment the Pp-IX distribution demonstrated by LIF showed a demarcation between tumour and normal skin of about 15:1 for BCC and Bowen's disease, and 5:1 for T-cell lymphomas. Laser light from a pulsed frequency-doubled Nd:YAG laser pumping a dye laser with light emission at 630 nn was used for the therapy. The power density in the irradiation was kept below 110 mW/cm(2), in order to avoid hyperthermal effects. A total energy of 60 J/cm(2) was delivered for 10-20 min, depending on the tumour size. A complete response rate of 100% in superficial BCCs and 64% in nodular BCCs occurred after a single laser treatment, and a response rate of 100% was achieved after one additional. treatment in the nodular BCCs. in the Bowen's disease lesions a complete response of 90% was obtained with a single treatment. Two of the four T-cell lymphomas resolved completely. The follow-up time was between 6 and 14 months.

Evaluation of Photodynamic Therapy of Skin Cancers with Partial Differential Alpha-Aminolevulinic Acid.

Treatment of Primary Carcinomas of Facial Skin by Photodynamic Therapy with Topical Δ-Aminolaevulinic Acid

Treatment of skin cancer and pre-cancer using topical ALA-PDT—A single hospital experience

Photodynamic Therapy of Bowen's Disease Using 5-Aminolevulinic Acid

Application of 5‐aminolevulinic Acid‐photodynamic Therapy in Common Skin Diseases

Advances in the Treatment of Skin Diseases with Δ-Aminolevulinic Acid-Based Photodynamic Therapy

Photodynamic Therapy of Non-Melanoma Skin Malignancies with Topical Delta-Amino Levulinic Acid - Diagnostic Measurements

Photodynamic therapy for the treatment of 18 cases of skin tumors

Therapeutic and immune effects of 5-aminolevulinic acid photodynamic therapy on UVB-induced squamous cell carcinomas in hairless mice.

Topical 5-Aminolevulinic Acid-Mediated Photodynamic Therapy for Oral Verrucous Hyperplasia, Oral Leukoplakia and Oral Erythroleukoplakia

Photodynamic therapy as an alternative treatment in patients with invasive cutaneous SCC where surgery is not feasible: Single center experience

Photodynamic Therapy of Basal Cell Carcinoma and Factors Affecting the Response to Treatment

Photodynamic therapy of non-melanoma malignant tumours of the skin using topical delta-amino levulinic acid sensitization and laser irradiation.

Evaluating the safety and efficacy of aminolevulinic acid 20% topical solution activated by pulsed dye laser and blue light in the treatment of facial cutaneous squamous cell carcinoma in situ

ALA-PDT successfully treated multiple cSCC in situ and AK in a patient with Epidermodysplasia verruciformis

Therapeutic and fluorescence evaluation of 20% 5-aminolevulinic acid-mediated photodynamic therapy in actinic keratosis

Review of Dermatology Use of 5-Aminolevulinic Acid Photodynamic Therapy in China from 1997 to 2013

5-Aminolevulinic Acid Photodynamic Therapy for Early-Stage Lip Squamous Cell Carcinoma

Treating Cutaneous Squamous Cell Carcinoma Using 5-Aminolevulinic Acid Polylactic-Co-Glycolic Acid Nanoparticle-Mediated Photodynamic Therapy in A Mouse Model

Low-dose Topical 5-Aminolevulinic Acid Photodynamic Therapy in the Treatment of Different Severity of Acne Vulgaris.

Topical Photodynamic Therapy of Squamous Cell Carcinomas in a Hairless Mouse Model